SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma
Iris Sze Ue Luk(Fred Hutch Cancer Center), Sita Kugel(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Wilhelm Haas(Harvard University), Myriam Boukhali(Harvard University), Angela Yu(Fred Hutch Cancer Center), Liberalis Debraj Boila(Fred Hutch Cancer Center), Caroline M. Bridgwater(Fred Hutch Cancer Center), Naomi Yamamoto(University of Washington), Supriya K. Saha(Diamond Harbour Women's University), Meena Kathiresan(Harvard University Press), Heidi L. Kenerson(University of Washington), Tian V. Tian(Breast Cancer Research Foundation), Mariana Yáñez-Bartolomé(Hebron University), Taylor S. Hulahan(Medical University of South Carolina), Jonathan A. Cooper(Fred Hutch Cancer Center), Raymond S. Yeung(University of Washington), Aaron Lampano(Fred Hutch Cancer Center), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Lucas B. Sullivan(Fred Hutch Cancer Center), David Sokolov(Fred Hutch Cancer Center), I. Engström(Fred Hutch Cancer Center), Paul D. Lampe(Fred Hutch Cancer Center)
Cited by 15
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif
|The EMBO Journal|2006|415